Neuroligin-1 is altered in the hippocampus of Alzheimer’s disease patients and mouse models, and modulates the toxicity of amyloid-beta oligomers

Julien Dufort-Gervais1,2, Chloé Provost2, Laurence Charbonneau3, Christopher M. Norris4, Frédéric Calon5,6, Valérie Mongrain2,3,7 & Jonathan Brouillette1,2,7

Synapse loss occurs early and correlates with cognitive decline in Alzheimer’s disease (AD). Synaptotoxicity is driven, at least in part, by amyloid-beta oligomers (Aβo), but the exact synaptic components targeted by Aβo remain to be identified. We here tested the hypotheses that the post-synaptic protein Neuroligin-1 (NLGN1) is affected early in the process of neurodegeneration in the hippocampus, and specifically by Aβo, and that it can modulate Aβo toxicity. We found that hippocampal NLGN1 was decreased in patients with AD in comparison to patients with mild cognitive impairment and control subjects. Female 3xTg-AD mice also showed a decreased NLGN1 level in the hippocampus at an early age (i.e., 4 months). We observed that chronic hippocampal Aβo injections initially increased the expression of one specific Nlgn1 transcript, which was followed by a clear decrease. Lastly, the absence of NLGN1 decreased neuronal counts in the dentate gyrus, which was not the case in wild-type animals, and worsens impairment in spatial learning following chronic hippocampal Aβo injections. Our findings support that NLGN1 is impacted early during neurodegenerative processes, and that Aβo contributes to this effect. Moreover, our results suggest that the presence of NLGN1 favors the cognitive prognosis during Aβo-driven neurodegeneration.

Synapse loss occurs early in the pathogenesis of Alzheimer’s disease (AD) and correlates with cognitive decline of the patients1–3. Hippocampus-dependent memory for recent facts and events (explicit memory) is among the first type of memory that is affected in the disease because of the neurodegenerative process that rapidly and gradually takes place in the hippocampus at the onset of AD4,5. More precisely, within the hippocampal network, the perforant path that connects the entorhinal cortex to the dentate gyrus (DG) is one of the earliest and most severely affected pathways in AD6,7. This suggests that the DG is among sites showing initial signs of synaptic dysfunction, including in glutamatergic transmission8, and that it could represent an area of particular relevance for early interventions.

Despite decades of research focused on the amyloid-beta (Aβ) peptide, its causal role in AD pathogenesis remains unclear at the molecular level. However, strong evidence suggests that soluble Aβ oligomers (Aβo) are particularly neurotoxic and that their presence can correlate with memory deficits in AD patients and animal models, especially when considering oligomers derived from Aβ1-42 peptides9–18. Soluble Aβo start to accumulate in the human brain ~10 to 15 years before clinical symptoms and were shown to induce losses of excitatory synapses and neurons19–22. The oligomerization of Aβ is rapid and it has been suggested that Aβ toxicity results...
from multiple small A\(\beta\) species present at the same time, rather than from one particular type of soluble oligomer\(^{1,16,22,24}\). Although the toxicity (including synaptotoxicity) of soluble A\(\beta\) is well established, specific synaptic components that are altered when A\(\beta\) begin to increase in the brain at the onset of AD remain to be identified. Identifying A\(\beta\)-driven changes in pre-synaptic proteins specifically quantifying is required to understand glutamatergic synaptic dysfunction and loss, which likely takes place before neurodegeneration induces substantial and irreversible brain damage permanently affecting cognition and autonomy.

Neuroligins (NLGNs) are post-synaptic adhesion proteins that interact with pre-synaptic protein neuromodulators (NRXNs) and have roles in synapse formation, maturation, maintenance and plasticity\(^{25-27}\). Neuroligin-1 (NLGN1) predominantly localizes at excitatory post-synaptic densities\(^{28}\), and previous work has linked it to neuropsychiatric and neurological disorders such as autism, schizophrenia and stroke\(^{29-33}\). Interestingly, NLGN1 has also been shown to be involved in synaptic plasticity, N-methyl-D-aspartate (NMDA) receptor function, memory and sleep regulation\(^{35,32,33}\), which are all altered in AD. The relevance of NLGN1 (and NRXNs) in the context of AD neurodegeneration has been emphasized in the last decade\(^{34,35}\). In fact, a single dose of A\(\beta_{\text{31-40}}\) fibrils has been shown to negatively impact NLGN1 in rats, which impaired synaptic function and memory\(^{36}\). In addition, A\(\beta\) were shown to bind to NLGN1 in vitro, and interfering with this interaction was observed to modulate synaptic integrity\(^{37,38}\). Moreover, NLGN1 was recently shown to be decreased in the plasma of patients with AD as well as in the preclinical period\(^{39}\). Nonetheless, to the best of our knowledge, it remains to be determined whether NLGN1 is altered in the hippocampus of AD patients as well as whether it is involved in the specific hippocampal pathology induced in vivo by soluble low-molecular-weight A\(\beta_{\text{30-42}}\).

Therefore, we here aimed to fill this knowledge gap using quantifications of the NLGN1 level in the hippocampus of patients with AD as well as in two animal models with A\(\beta\)-driven neurodegeneration. Importantly, we assessed the timeline so far without performing in patients with amnestic mild cognitive impairment (aMCI), in triple transgenic (3xTg-AD) mice of 4, 12 and 18 months, and in mice submitted to 2, 4 and 6 days of A\(\beta_{\text{30-42}}\) injection in the hippocampus. In addition, we tested whether the absence of NLGN1 aggravates memory impairment and neuronal losses caused by A\(\beta_{\text{30-42}}\) using chronic hippocampal A\(\beta_{\text{30-42}}\) injections combined to immunohistochemistry and assessments of spatial and working memory. We found that the level of NLGN1 is decreased in the hippocampus of aMCI and AD patients and in young 3xTg-AD female mice, and that hippocampal A\(\beta_{\text{30-42}}\) injections decreased neuronal count in the DG and induced spatial learning deficits predominantly in Nlgn1 knockout (KO) mice. Our results provide support to the hypothesis that NLGN1 is impacted early during A\(\beta\) pathology and that it modulates cognitive functions during A\(\beta\)-driven neurodegeneration.

Methods

**Human brain tissues.** Hippocampal protein samples from individuals with aMCI, AD patients and age-matched non-demented control subjects (CTRL) were provided by the brain bank of the Alzheimer’s Disease Center of the University of Kentucky\(^{40}\). AD and aMCI were diagnosed using clinical evaluations as previously described\(^{40}\). Briefly, cognitive status, neurologic and physical examinations were performed annually or biannually with a follow up of at least 2 years before death. All subjects had no comorbidity with substance abuse, head injury, encephalitis, meningitis, epilepsy, stroke, infectious disease or major psychiatric illness. Mini-mental status examinations (MMSE) were performed as previously described\(^{41}\). Briefly, cognitive status, neurologic and physical examinations were performed annually or biaxinically with a follow up of at least 2 years before death. All subjects had no comorbidity with substance abuse, head injury, encephalitis, meningitis, epilepsy, stroke, infectious disease or major psychiatric illness. Mini-mental status examinations (MMSE) score was used as an indicator of overall cognitive status\(^{41}\), with a lower score being indicative of deficits in memory, attention, orientation and/or language. MMSE score was on average 24.4 and 7.8 in aMCI and AD patients, respectively (Table 1). Cognitive state was also evaluated with the animal naming test (ANIMALS: number of animals named in 1 min, with 12 generally considered as the cutoff for impairment), the Boston naming test (BNT: 15-item version with lower score indicating deficits), and the controlled oral word association test (COWA: sum of three trials of verbal fluency, lower score indicating impairment; Table 1). CTRL subjects were at Braak stage 0 or 1 and scored on average 27.8 on the MMSE (Table 1). Subjects were selected based on the shortest post-mortem interval (PMI) available to avoid protein degradation (Table 1). Other characteristics of patients and subjects are also listed in Table 1. Protocols for subjects and patients examinations and for the use of postmortem human brain tissue were approved by the University of Kentucky Institutional Review Board, and informed consent was obtained from all participants. All methods were performed in accordance with relevant guidelines and regulations.

**Animals.** Male and female 3xTg-AD (APPSwe, PS1M146V, tauP301L) mice\(^{42}\), and control non-transgenic mice of the same genetic background (i.e., C57BL/6-129/SvJ) were produced and maintained at the animal facility of the Research Center of the Centre Hospitalier de l’Université Laval as previously described\(^{43}\). Male C57BL/6, Nlgn1 KO mice and wild-type (WT) littermates were used for chronic A\(\beta_{\text{30-42}}\) injections. C57BL/6 J mice (n = 41) were purchased from Jackson Laboratories, backcrossed with C57BL/6 J mice for >10 generations, and bred at the animal facility of the Research Center of the Hôpital du Sacré-Coeur de Montréal. KO and WT mice were implanted with cannulae for intra-hippocampal A\(\beta\) injections at 24 ± 10 weeks. Animals were housed individually and maintained in a 12 h light/12 h dark cycle at a temperature of 24 ± 1 °C with food and water available ad libitum. The experiment involving 3xTg-AD mice was approved by the Animal Welfare Committee of the Université Laval according to guidelines of the Canadian Council on Animal Care. All other experimental procedures were approved by the Comité d'éthique de l'expérimentation animale du Hôpital du Sacré-Coeur de Montréal (Recherche CIUSSS-NIM) also in accordance with guidelines of the Canadian Council on Animal Care.

**A\(\beta_{\text{30-42}}\) preparation and A\(\beta\) quantification.** Preparation of the A\(\beta_{\text{30-42}}\) and control A\(\beta_{\text{1-42}}\) scrambled (A\(\beta\)-Scr) solutions were performed as previously described\(^{44}\). Briefly, synthetic A\(\beta_{\text{1-42}}\) and A\(\beta\)-Scr (rPeptide, Cat
Hippocampal soluble Aβ

Table 1. Characteristics of humans from which brain samples were collected.

| Characteristics | Units | CTRL | aMCI | AD |
|-----------------|-------|------|------|----|
| Age             | years | 86.9 ± 1.7 | 89.5 ± 1.6 | 86.1 ± 1.2 |
| Sex             | ♂ (n) | 7 | 5 | 6 |
|                 | ♀ (n) | 5 | 6 | 7 |
| PMI             | hours | 3.1 ± 0.1 | 3.7 ± 0.7 | 3.3 ± 0.2 |
| NFTs            | #/mm³ | 2.5 ± 1.4² | 12.2 ± 4.0 | 33.3 ± 6.9² |
| Hippocampal soluble Aβ | μmol/g | 220.0 ± 135.1³ | 2006.8 ± 733.4⁴ | 5763.9 ± 1364.3⁴ |
| MMSE            | score | 27.8 ± 0.7 | 24.4 ± 1.0 | 7.8 ± 2.3⁴ |
| ANIMALS         | score | 13.1 ± 1.5 | 13.7 ± 1.7⁵ | 11.4 ± 2.2⁵ |
| BNT             | score | 14.1 ± 0.3 | 13.9 ± 0.4⁶ | 12.3 ± 1.4⁶ |
| COWA            | score | 38.3 ± 3.7 | 35.0 ± 4.1⁷ | 28.7 ± 5.7⁷ |

Table 1. Characteristics of humans from which brain samples were collected. CTRL: control subjects; aMCI: amnesic mild cognitive impairment subjects; AD: Alzheimer’s disease patients; PMI: post-mortem interval; NFTs: neurofibrillary tangles; Aβ: amyloid-beta; MMSE: mini-mental state examination; ANIMALS: animal naming test; BNT: Boston naming test; COWA: controlled oral word association test. Some aMCI and AD patients could not complete some cognitive tests. *n = 11; ²n = 8, ³n = 5; ⁴n = 9; ⁵n = 10; ⁶n = 7; ⁷n = 6.

No. A-1163-2 and A-1004-1, respectively) were suspended in hexafluoropropanol (HFIP) (Acros Organics, Cat No. 14754100). The HFIP was evaporated with nitrogen gas and Aβ₁-42 peptides were resuspended in DMSO (Sigma-Aldrich, Cat No. D-4540). The solution was eluted through a HiTrap desalting column (GE Healthcare, Cat No. 17-1408-01) previously equilibrated with a Tris-EDTA solution (50 mM Tris, 1 mM EDTA). Aβ₁-42 peptides were quantified using the BCA protein assay kit (Thermo Fisher, Cat No. 23225) and stored at −80°C. The average concentration of the solutions used in this study was 0.28 ± 0.04 μg/μL. The biophysical and biological properties as well as the level of oligomerization of this Aβ preparation have been previously characterized. The Aβ solution was kept at room temperature for 1 h before injection to induce oligomerization and produce soluble low-molecular-weight Aβ₁-42, as previously done. Soluble Aβ quantification in post-mortem tissue was performed by a standard three-step serial extraction procedure as described elsewhere for these samples. The Aβ quantification was not available for 4 CTRL, 6 aMCI and 4 AD patients (Table 1).

Surgical procedure and injections. The cannula implantation surgery was adapted from the procedure previously described. Briefly, mice were anesthetized with Ketamine/Xylazine (120/10 mg/kg), installed on a stereotaxic apparatus and maintained under anesthesia using 1% isoflurane. Stereotaxic coordinates of the two cannulas implanted just above the DG were defined as 2.3 mm posterior to the bregma, ±1.5 mm from midline and 1.8 mm below the skull surface. Three screws were inserted into the skull to stabilize cannulas fixed to the skull with dental cement. Mice were given buprenorphine (0.1 mg/kg) immediately after the surgery and the day after to ensure sufficient analgesia.

The injections were conducted as previously described. In brief, one week after recovery, freely moving mice were injected with Aβ solutions or an equal volume of control AβSc or vehicle (VH: 50 mM Tris, 1 mM EDTA) Aβ₁-42 peptides were quantified using the Pierce BCA protein assay kit. Thirty μg of proteins per sample were separated by electrophoresis using Bolt 4-12% Bis-Tris gels (Thermo Fisher, Cat No. NW04122BOX) and transferred onto a PVDF membrane (Immobilon-P, Cat No. ISEQ00010). Membranes were incubated 1 h with Odyssey blocking buffer (Type PBS) (LiCor, Cat No. 927-40000) at room temperature and incubated overnight at 4°C with anti-NLGN1 antibodies (Millipore, Cat No. MABN742, used at 1:1000 for human samples; Synaptic Systems, Cat No. 129 111, used at 1:1000 for all non-human samples), anti-PSEN1 antibodies (Millipore, Cat No. 04-1066, 1:1500), or anti-GAPDH antibodies (Cell Signaling Technology, Cat No. 5174, 1:1000) diluted in Odyssey blocking buffer (Type PBS) containing 0.2% Tween 20 (Fisher BioReagents, Cat No. BP337-500). Membranes were then washed and incubated with corresponding secondary antibodies (LiCor, IRDye 800CW, 1:15000; IRDye 680RD, 1:15000; Cell Signaling Technology, HRP linked antibody No. 7076, 1:1000) diluted in Odyssey blocking buffer (Type PBS) containing 0.2% Tween 20 and 0.01% SDS for 1 h at room temperature. Membranes were revealed using the Odyssey CLx (LiCor, Cat No. 9140) with Image Studio 3.1 software. For some blots, chemiluminescence was visualized using an ECL detection kit (Thermo Scientific, Cat No. 1859022). Quantitative densitometric analysis was performed using ImageJ and expressed relative to
GAPDH. At least one control sample was loaded on each blot as a calibrator for quantification. Full length blots are presented in Supplementary Information.

mRNA extraction and qPCR. mRNA extraction, reverse transcription and qPCR procedures were performed as previously described48–50. Briefly, hippocampal mRNA was extracted using the RNeasy Lipid Tissue mini kit according to manufacturer’s instructions (Qiagen, Cat No. 74804). Reverse transcription was performed with SuperScript II Reverse transcriptase (Invitrogen, Cat No. 18064014) following the manufacturer’s instructions including 10 min at 25 °C and 60 min at 42 °C. QPCR was performed using 384-well plates with a mix of RNAase free water, TaqMan Fast Advanced Master Mix (Applied Biosystems, Cat No. 4444557), and primers and probes for each gene (Table 2). Given that NLGN1 has isoforms with different properties51, five different probe sets were used to quantify Nlgn1 expression as previously performed48–50. Nlgn1A corresponds to the sequence containing insert A and Nlgn1B with insert B, while Nlgn1NA is a sequence without insert A and Nlgn1NB without insert B. Nlgn1C corresponds to a common sequence targeting transcripts with only insert A, only insert B, both inserts and no insert. The expression of four additional genes coding for related synaptic proteins have also been quantified (Nlgn2, Nrxn1, Nrxn2, Nrxn3). Three endogenous control genes (GusB, Rps9 and Tbp) were quantified to normalize expression level of Nlgn1 variants and of related mRNA. Gene expression was measured using a Viia 7 thermal cycler (Thermo Fisher) with the following cycling conditions: 2 min at 50 °C, 20 sec at 95 °C, 40 times 1 sec at 95 °C and 20 sec at 60 °C. The analysis was performed with Expression Suite (Life Technologies), which calculated gene expression relative to endogenous controls and to one sample of the control group (modified delta delta Ct).

Primary hippocampal culture and cell viability. The primary neuronal culture procedure was carried out as described previously42. Briefly, pregnant Long-Evans female rats were ordered from Charles River Laboratories and sacrificed at embryonic day 18. Hippocampi were dissected, transferred to a tube containing HBSS (Sigma-Aldrich, Cat No. H1641), HEPES (Gibco, Cat No. 15630-080), penicillin/streptomycin/amphotericin (Gibco, Cat No. 15240-062) and 3 mM sodium pyruvate (Gibco, Cat No. 25080-094) at 37 °C, and were

Table 2. List of probes and primers used for qPCR. BHQ1: Black Hole Quencher-1 GusB: beta-glucuronidase B; Nlgn1A: neuroligin-1 with insert in splice site A; Nlgn1NA: neuroligin-1 without insert in splice site A; Nlgn1B: neuroligin-1 with insert in splice site B; Nlgn1NB: neuroligin-1 without insert in splice site B; Nlgn1C: neuroligin-1 common to all transcript variants; Nlgn2: neuroligin-2; Nrxn1: neurexin-1; Nrxn2: neurexin-2; Nrxn3: neurexin-3; Rps9: ribosomal protein S9; Tbp: TATA-box binding protein; FAM: 6-carboxyfluorescein; TAMRA: tetramethylrhodamine.
treated with 0.25% trypsin (Life Technologies, Cat No. 15090-046), agitated at 900 rpm for 15 min at 37 °C, and dissociated by trituration. Cells were plated in 12-well plates (Costar, Cat No. 3513) coated with poly-D lysine hydrobromide (Sigma-Aldrich, Cat No. P6407-5MG) and containing minimum essential medium (Sigma-Aldrich, Cat No. M0275) supplemented with 10% horse serum (Sigma-Aldrich, Cat No. H1138), 3 mM sodium pyruvate, 25 mM D-Glucose (Sigma, Cat BP-250), 2 mM GlutaMax (Sigma, Cat No. RPNB9302), and 1% penicillin/streptomycin/amphotericin. Plates were incubated at 37 °C with 5% CO2 overnight, and the initial culture medium was replaced the day after with Neurobasal medium (Gibco, Cat No. 21103-049) supplemented with 2% B27 (Gibco, Cat No. 17504-044), 2 mM GlutaMax, and 0.5% penicillin/streptomycin/amphotericin. Primary hippocampal cells were cultured for 7 days before starting treatments. For Western blot analysis, cells were washed with cold 10 mM PBS, scratched off the wells with 140 μL of cold RIPA 1X buffer containing CHAPS and phosphatase and protease inhibitors, and rapidly stored at −80 °C. Protein extraction and Western blotting were performed as described above.

Cell viability was measured using the CellTiter 96 AQicro Titer One Solution Cell Proliferation Assay (Promega, Cat No. G3581) according to the manufacturer’s protocol. Briefly, the CellTiter 96 AQicro Titer One Solution reagent was added to the Neurobasal medium containing the cells (v/v ratio of 1:5) and after 1.5 h of incubation at 37 °C the absorbance was recorded at 490 nm. The tested conditions were normalized to values obtained with water-treated wells.

**Spatial object recognition (SOR) test.** The SOR task was conducted 24 hours after the last hippocampal injection (Supplementary Fig. 1) in Nlgn1 KO mice and wild-type (WT) littermates similar to previously described. It was done in an opaque plastic arena (45 × 45 cm) with the floor covered with litter that was mixed after each trial to eliminate olfactory cues. The four walls contained different visual cues and two different objects were placed in adjacent corners of the arena. The walls and objects were cleaned with 70% ethanol between each mouse. During the first day, mice explored the arena and objects for 5 min. Twenty-four hours later, one of the two objects was moved to the opposite corner of the arena and mice were reintroduced in the arena for 5 min. The number of interactions with each object, defined as a touch of the snout or sniffing of the object by the mouse, was counted by an experimenter blind to the genotype and treatment. The discrimination index (DI) was calculated for the number of interactions according to the following formula: (moved object - fixed object)/(moved object + fixed object).

**Y-maze test.** A two-trial Y-maze task was performed 48 hours after the SOR test (Supplementary Fig. 1) as previously described. The three arms of the Y maze were 39 cm long, 15 cm wide and 40.5 cm high. The floor of the maze was covered with litter and different visual cues were placed at the top of the end of each arm. During the first trial, mice were placed at the end of one arm and were allowed to explore the two arms of the maze freely during 5 min without access to the third arm. The blocked arm was alternated between each mouse. Mice were returned to their home cage for 5 min and then reintroduced into the same starting arm of the Y-maze to explore all three accessible arms for 2 min. Movements of the mouse were analyzed using the Smart acquisition software (Harvard Apparatus) to extract time spent in the new arm and the average time spent in the other two arms. The walls were cleaned with 70% ethanol and the litter was mixed between each mouse to avoid olfactory cues.

**Morris water maze (MWM) test.** The MWM task was conducted 48 hours after the Y-maze test (Supplementary Fig. 1) as previously described. Mice were trained in a 120-cm diameter pool filled with water rendered opaque by adding non-toxic white paint. The temperature of the water was kept at 24 ± 1 °C during testing. During the first 4 days, mice had to learn to find a submerged platform in the pool using visuo-spatial cues installed around the pool. Mice had 3 trials per day with 30 min between each trial. If the mouse failed to reach the platform within 60 sec, it was guided to the platform and had to remain on the platform for 10 sec before being removed from the pool. The time and distance to reach the platform were extracted by the Smart software (Harvard Apparatus). Starting location of the mice was different for each trial. During the probe trial on the fifth day, the platform was removed and mice had 60 sec to explore the pool. The time spent in the target quadrant that previously contained the platform and in the other quadrants, as well as the number of times the mouse crossed the area around the platform (2x the diameter of the platform) were calculated with the Smart software. A final cued task of 3 trials was also performed to verify visual acuity and motivation to escape from water. During this test, mice had a maximum of 30 sec to reach a visible platform that was moved in a different quadrant between each trial. Data were acquired in real time with the Smart software.

**Immunofluorescence (IF) staining.** Neurons were marked with the NeuN antibody for neuronal counting purpose, as described below. Staining also served to validate the adequate positioning of cannulas. Brains were cut with a HM525NX cryostat (Thermo Scientific, Cat No. 956640) at −20 °C and 10 μm coronal slices were mounted on SuperFrost Plus slides (Fisher Scientific, Cat No. 12-550-15). Hippocampal sections were performed at ±100 μm from the middle of the injection site. Brain slices were mounted in series on 6 slides, with 4 slices per slide. Slides were fixed for 15 min in 10% formalin (Sigma-Aldrich, Cat No. HT501128) and washed with PBS (Cell Signaling Technology, Cat No. 98085). Sections were immersed in a blocking solution (1X PBS, 5% goat serum (Cell Signaling Technology, Cat No. 5425), 0.3% Triton X-100 (Fisher BioReagents, Cat No. BP151-500) for 60 min at room temperature and incubated overnight at 4 °C with anti-NeuN antibodies (Cell Signaling, Cat No. 24307; 1:1000) diluted in PBS 1X, 1% BSA (Fisher BioReagents, Cat No. BP1600-100) and 0.3% Triton X-100. The slides were washed, and incubated with a secondary antibody (Alexa fluor 488, Cell Signaling Technology, Cat No. 4340, 1:1000) for 90 min at room temperature and protected from light. Slides were then washed, dried and one drop of Prolong Gold Antifade DAPI (Cell Signaling Technology, Cat No. 8961S) was applied on each section before being covered with a coverslip (Thermo Scientific, Cat No. 102455).
Microscopy. A Zeiss AxioImager 2 fluorescence microscope, a monochrome camera, and the StereoInvestigator software (MBF Biosciences) were used to acquire IF images. Wavelength filters of 488 nm and 350 nm were used to excite the fluorochromes of the secondary antibody and of DAPI. Neuronal counting was performed using the Neurolucida Software (MBF Biosciences). The 20X objective was used to precisely identify the depth of the injection site. Two mice were excluded from neuronal count and memory assessments because the cannula was positioned outside the target region. Using the 40X objective, a 500 μm wide area was defined in the DG under the injection site as well as in CA2-CA3 distant to the injection site. Since there was little or no cell overlay using 10 μm sections and that NeuN labeling was well defined, the function Detect Cells of the Neurolucida program could discriminate between individual cells. This function made it possible to make a reliable cell count in the area under the injection site and the distant area, which has been validated by manual counting by a blind experimenter. Three to four sections per slide were counted; the average of these sections was calculated and analyzed according to genotype and treatment.

Statistical analyses. Statistical analyses of multiple samples were performed using appropriate analyses of variance (ANOVA). One-way ANOVA was used for human sample analysis; two-way ANOVA was used to analyze results of 3xTg-AD mice, cell culture, chronic injections, IF, and most variables of the SOR and MWM tests; three-way ANOVA was used for the MWM training phase. Significant effects were decomposed, when appropriate, using planned comparisons. Student t tests were used for some analyses of the SOR and the Y-maze. Pearson’s correlations were performed to quantify the association between soluble Aβ and NLGN1 level. The sizes of the different samples were determined on the basis of previous studies in the field. Statistical analyses were performed using GraphPad Prism 6.0 and/or JMP 14. Significance threshold was set at 0.05 and the levels of statistical significance are identified with *p < 0.05, **p < 0.01, ***p < 0.001. Data are reported as mean ± SEM. The number of samples used for each experiment is reported in figure legends.

Results

Lower NLGN1 in AD patients. We first assessed whether the hippocampal level of NLGN1 is decreased in AD patients and in individuals with aMCI, a prodromal stage of AD55,56. We found that aMCI individuals have lower levels of NLGN1 in the hippocampus compared to age-matched CTRL without cognitive impairment (p < 0.001; Fig. 1A, Supplementary Fig. 2A). Also, NLGN1 level was found to be significantly lower in AD patients (n = 11) and AD patients (n = 11) but not in CTRL (n = 12).
patients when compared to both aMCI individuals (p < 0.05) and CTRL (p < 0.001). These results suggest that there is a decline in human hippocampal NLGN1 level that is matching disease progression. In addition, when expressed relative to the synaptic marker PSD95, NLGN1 was significantly decreased in both aMCI and AD in comparison to CTRL (p < 0.05; Supplementary Fig. 2B,C), which indicates that the NLGN1 decrease is larger than that of PSD95 previously reported to occur early during the neurodegenerative process53. Moreover, we found that, in aMCI individuals and AD patients, lower hippocampal level of NLGN1 significantly correlates with higher hippocampal level of soluble Aβ (p < 0.01; Fig. 1B) as well as with poorer cognitive state assessed with the MMSE (p < 0.01; Fig. 1C).

**Lower NLGN1 level in young 3xTg-AD female mice.** To further evaluate the fate of NLGN1 in the course of neurodegeneration, we measured NLGN1 hippocampal levels in 3xTg-AD male and female mice at three different ages (4, 12 and 18 months). This commonly used AD model shows beta-amyloid plaques and neurofibrillary tangles with intracellular Aβ accumulation in the hippocampus at 4 months that correlates with...
cognitive deficits. Female 3xTg-AD mice showed considerably lower NLGN1 level at 4 months in comparison to control female (p < 0.001; Fig. 2A, Supplementary Fig. 3). NLGN1 level did not significantly differ between female 3xTg-AD and control mice at 12 and 18 months. In male mice, NLGN1 hippocampal level did not significantly differ between 3xTg-AD and controls at all ages studied (Fig. 2B, Supplementary Fig. 3). Interestingly, NLGN1 level decreased with age in males, with a significant difference specifically observed between 4 and 18 months (p = 0.01). In summary, these data indicate that NLGN1 is rapidly decreased in 3xTg-AD mice, and that this decrease is specific to female mice.

NLGN1 level is decreased by Aβo1-42 exposure in vitro. Given our observation that NLGN1 level significantly correlates with soluble Aβ in the human hippocampus (Fig. 1B), we next verified whether Aβo1-42 could directly impact NLGN1 level in vitro, and whether this is linked to neuronal survival. NLGN1 protein level and cell viability were measured in primary culture of hippocampal neurons treated with 2 μM of Aβo1-42 for 48 or 72 hours. As expected from our previous study, Aβo1-42 significantly decreased neuronal viability by about 40% after 72 hours of treatment (p < 0.001; Fig. 3A). No change in viability was observed after 48 hours of treatment. NLGN1 protein level was also decreased after 72 hours of Aβo1-42 exposure (p < 0.02) and unchanged after 48 hours (Fig. 3B, Supplementary Fig. 4). These data indicate that Aβo1-42 exposure is detrimental to NLGN1 protein level in hippocampal neurons, which follows a time course similar to neuronal viability.

Nlgn1 mRNA is affected by hippocampal Aβo1-42 injections. We next aimed at identifying the specific impact of Aβo1-42 on NLGN1 in vivo using chronic (2, 4 or 6 days) hippocampal injections in WT mice. In addition, we assessed whether Aβo1-42 affect Nlg1 in a transcript variant-dependent manner, which can be done by measuring mRNA expression using different probe sets targeting the presence or absence of the two NLGN1 inserts. Two days of Aβo1-42 injections significantly increased the hippocampal expression of amplicons Nlg1NA (p < 0.04) and Nlg1NC (p < 0.02) in comparison to control injections (Fig. 4B,E); whereas 4 days

---

**Figure 3.** Aβo1-42 exposure impacts cell viability and NLGN1 in primary neuronal culture. (A) Neuronal viability of hippocampal neurons exposed to 2 μM of Aβo1-42 or vehicle (VH) for 48 and 72 hours. A significant Treatment-by-Time interaction was found (two-way ANOVA F1,39 = 12.6, p = 0.001), with difference between Aβo1-42 and VH restricted to 72 hours of treatment (stars indicating planned comparison, also in B). (B) NLGN1 protein level in primary culture of hippocampal neurons was assessed by Western blot (top) and expressed relative to the control protein GAPDH (bottom) after exposure to 2 μM of Aβo1-42 or VH for 48 and 72 hours. A significant Treatment-by-Time interaction was also found (two-way ANOVA F1,22 = 5.43, p = 0.03), with difference between Aβo1-42 and VH also restricted to 72 hours of treatment. Full length blots are shown in Supplementary Fig. 4. The number of replicate is indicated on each bar.
of injections significantly decreased the expression of amplicons Nlgn1NA (p < 0.04), Nlgn1NB (p < 0.05) and Nlgn1C (p < 0.01) (Fig. 4B,D,E). The Nlgn1A and Nlgn1B amplicons were not significantly changed by Aβo1-42 injections (Fig. 4A,C). Also, hippocampal Aβo1-42 injections did not significantly affect the gene expression of the related synaptic proteins NLGN2, NRXN1, NRXN2 and NRXN3 (Supplementary Fig. 5). NLGN1 protein level, which was measured in the hippocampus of the other hemisphere, showed a tendency to be decreased by 4 days of Aβo1-42 injections similar to specific Nlgn1 amplicons (Fig. 4F, Supplementary Fig. 6), but the change did not reach statistical significance (p < 0.2). These results suggest a transcript variant-specific impact of Aβo1-42 on the expression of Nlgn1, and that this impact shows a bi-phasic time course with an initial increase followed by a decrease.

**NLGN1 deletion worsens spatial learning deficits after treatment with Aβo1-42.** We next tested the functional role of NLGN1 specifically in Aβo-induced in vivo damage. We first investigated the implication of NLGN1 specifically in Aβo-driven memory impairment using assessments of spatial and working memory, selected for their dependency on the hippocampus58,59. This was done using Nlgn1 KO mice and WT littermates submitted solely to 4 days of injections of Aβo1-42 or AβScr (Supplementary Fig. 1). The condition with 4 injection days was selected given that it specifically decreased expression of precise Nlgn1 transcripts (Fig. 4) and to obtain...
an exposure to Aβ<sub>1-42</sub> intermediate in comparisons to 6 days that was shown to induce substantial neuronal loss and memory deficits.<ref>12</ref>

First, SOR was differentially affected by Aβ<sub>o1-42</sub> in Nlgn1 KO and WT mice. Indeed, the number of interactions with the moved object was significantly higher than the number of interactions with the fixed objects (t ≥ 2.6).<ref>

Figure 5. NLGN1 absence impairs spatial memory after Aβ<sub>1-42</sub> exposure. (A) Number of interactions with the fixed and moved objects in the SOR task for WT and Nlgn1 KO mice treated with Aβ<sub>1-42</sub> or AβScr. Stars indicate significant differences between moved and fixed objects (t ≥ 2.6). (B) A Genotype-by-Treatment interaction was found for the discrimination index (DI) in the SOR task (two-way ANOVA F<sub>1,34</sub> = 4.5, p = 0.04; stars indicate planned comparisons, also in E, F and J). (C) Percent time in the new and other arms in the Y-maze task for the four groups. Stars indicate significant differences between new and other arms (t ≥ 2.9). (D) Latency to the platform during the MWM training days showed significant effects of Genotype (three-way ANOVA F<sub>1,159</sub> = 5.4, p = 0.02) and Day (F<sub>3,151</sub> = 25.2, p < 0.0001) but no significant Genotype-by-Treatment-by-Day interaction (F<sub>3,159</sub> = 0.4, p = 0.7). (E) Latency to the platform during the MWM training trials showed significant Treatment-by-Trial (three-way ANOVA F<sub>3,151</sub> = 2.9, p = 0.03) and Genotype-by-Treatment (F<sub>1,159</sub> = 3.9, p < 0.05) interactions. (F) Graph of panel E Genotype-by-Treatment interaction showing the mean latency of all 12 trials. (G) Swimming speed during the MWM probe phase (two-way ANOVA Treatment F<sub>1,35</sub> = 0.06, p = 0.8; Genotype F<sub>1,35</sub> = 1.8 p = 0.2; interaction F<sub>1,35</sub> = 0.03, p = 0.9). (H) Number of platform crossing during the MWM probe phase showed a significant Treatment effect (two-way ANOVA F<sub>1,39</sub> = 6.2 p = 0.02). (I) Percent time in the target and other quadrants during the MWM probe test showed a significant Treatment-by-Quadrant interaction (three-way ANOVA F<sub>1,77</sub> = 8.6, p = 0.0045). (J) Percent time in the target quadrant showed for Aβ<sub>1-42</sub> and AβScr injected animals. The number of mice is 9-10 per group.
WT mice injected with AβScr (p = 0.004), WT mice injected with Aβo1-42 (p = 0.01) and KO mice injected with AβScr (p = 0.02), indicating memory for spatial location (Fig. 5A). However, Nlgn1 KO mice injected with Aβo1-42 did not differ in the number of interactions between the moved and fixed objects (p = 0.6), suggesting impaired spatial memory (Fig. 5A). This is also reflected in the DI, which was significantly lower in KO mice injected with Aβo1-42 than in all other groups (p = 0.002 vs. Nlgn1 KO mice with control injections; p = 0.001 vs. WT mice with control injections; p = 0.002 vs. WT mice with Aβo1-42 injections; Fig. 5B). These results indicate that only animals lacking NLGN1 express SOR memory deficits with intermediate exposure to Aβo1-42. In contrast, working memory in the Y-maze did not significantly differ between Nlgn1 KO and WT mice both under control and Aβo1-42 injections (Fig. 5C). All four groups indeed spent more time exploring the new arm in comparison to the other arms (p ≤ 0.001), which indicates preservation of working memory independent of the presence of NLGN1. The total distance traveled during the Y-maze test was equivalent between groups, whereas KO mice showed a small, but significant, decreased in the distance traveled during the SOR test (Supplementary Fig. 7).

Spatial memory was further tested in the MWM. As expected for the learning phase, the latency to reach the platform progressively decreased over training days (Fig. 5D). This decrease did not significantly differ between Nlgn1 KO and WT mice with Aβo1-42 and control injections, but the latency was globally higher in KO mice in comparison to WT mice (p = 0.02). When all trials of the 4 training days are considered separately (Fig. 5E), Aβo1-42 injected WT and KO mice showed a longer latency to reach the platform compared to AβScr injected WT and KO mice on the first trial of day 3 (p < 0.01). The first trial of each day was proposed to reflect memory retention25, for which deficits could be induced by Aβo1-42 independent of the genotype. Most importantly, Nlgn1 KO mice injected with Aβo1-42 showed a significant overall higher latency to the platform than all other groups (p < 0.01 vs. Nlgn1 KO mice with control injections; p < 0.01 vs. WT mice with control injections; p < 0.001 vs. WT mice with Aβo1-42 injections), which is also illustrated in Fig. 5F. These findings are reminiscent of observations in the SOR task and further support a greater impact of Aβo1-42 on spatial learning in the absence of NLGN1.

In the MWM probe phase, the platform is removed, and the number of times mice are crossing the zone where it was and the time spent in that quadrant where it was located (target quadrant) are indicative of spatial memory. Beforehand, we verified that the swimming speed did not significantly differ between WT and KO mice with Aβo1-42 and control injections (Fig. 5G). This confirmed equivalent locomotion across genotypes and treatments, and excluded this potential confounding in the evaluation of memory. We found that Aβo1-42 significantly reduced the number of platform crossing in the probe test independent of the genotype (p = 0.02; Fig. 5H).

Similarly, Aβo1-42 injected animals spent a lower percentage of time in the target quadrant compared to AβScr injected animals (p < 0.01; Fig. 5I). Indeed, Aβo1-42 injected WT and KO mice were not different from the 25% time spent in quadrant, which represents chance, while AβScr injected mice clearly spent more than 25% time in the target quadrant (Fig. 5J). Taken together, results from the MWM suggest that the absence of NLGN1 worsens the impact of Aβo1-42 on learning, but not on the final acquired memory.

**NLGN1 deletion reveals neuronal loss after treatment with Aβo1-42.** Lastly, we asked whether the absence of NLGN1 impacts neuronal loss in the DG caused by chronic hippocampal Aβo1-42 injections. This was assessed using the same mice as above tested for spatial and working memory. Neuronal loss was measured in the DG in an area located under the injection site (Fig. 6). The size of the counting area did not differ between groups (Fig. 6C). However, DG neuronal count was significantly decreased in Nlgn1 KO mice submitted to Aβo1-42 injections in comparison to all other groups (p = 0.02 vs. Nlgn1 KO mice with control injections; p = 0.002 vs. WT mice with control injections; p = 0.002 vs. WT mice with Aβo1-42 injections; Fig. 6D). Of note is that WT mice injected with Aβo1-42 did not significantly differ from WT mice with control injections, thus confirming an intermediate (sub-clinical) exposure to Aβo1-42. Neuronal count in a region distant to the injection site (i.e., CA2-CA3) revealed no significant difference between the four groups (Supplementary Fig. 8). These results suggest that the absence of NLGN1 potentiates the toxicity of Aβo1-42, leading to a noticeable neuronal loss in the DG.

**Discussion**

Our findings provide insight on the involvement of NLGN1 in neurodegeneration. We first report that NLGN1 protein is decreased in the hippocampus of aMCI individuals and AD patients, in whom its level correlates with soluble Aβ and cognitive function. We then found that NLGN1 protein is also decreased, at an early developmental age, in the hippocampus of a mouse model showing Aβ pathology. Further, we revealed that the specific exposure to Aβo1-42 decreases NLGN1 protein in hippocampal neurons in culture and modulates Nlgn1 hippocampal expression in a transcript variant-dependent manner. Importantly, we demonstrated a negative effect of the absence of NLGN1 on Aβo1-42 toxicity, with Nlgn1 KO mice showing neuronal loss and greater deficits in spatial learning when injected with Aβo1-42 compared to WT animals. These results are supporting an impact of Aβo1-42 on Nlgn1 as well as a modulatory role for NLGN1 in the toxicity induced by Aβo1-42.

To our knowledge, our study is the first to show that NLGN1 level in the hippocampus is decreased in aMCI individuals and AD patients. This result is in line with the recent report that NLGN1 is decreased in the plasma of AD patients and in individuals with less severe cognitive symptoms36, and may suggest that changes in the hippocampus could contribute to plasmatic changes. It also aligns with our previous findings of decreased synaptic proteins linked to glutamatergic transmission (e.g., PSD95, GluN2B) in the hippocampus of aMCI patients34. Our observation that the NLGN1 decrease is of greater magnitude than the PSD95 decrease emphasizes the particular relevance of considering the role of NLGN1 in neurodegeneration. Such a role is also supported by the observation of a NLGN1 mutation affecting its function in a patient with AD35. Moreover, the finding that NLGN1 level in the aMCI/AD hippocampus correlates with cognitive function supports the idea that synaptic dysfunction adequately predicts cognitive decline in AD1-32,2. Even if the exact mechanisms underlying NLGN1 modification in aMCI and AD remains to be identified, plasmatic NLGN1 or even hippocampal NLGN1 measured via imaging may be considered as an early biomarker of AD.
Importantly, we observed that the decrease in hippocampal NLGN1 protein is also an early event occurring in a recognized mouse model of AD (i.e., 3xTg-AD). Indeed, decreased NLGN1 was found at 4 months, an age at which cognitive symptoms are just starting to manifest and have been attributed to intraneuronal Aβ57. This model generally shows signs of neuronal death, human Aβ precursor protein (hAPP) deregulation, and Tau pathology later in life42,60,61, but these may all contribute to NLGN1 decrease together with alterations in Preselinin-1 in this model. The observation that only the females show this early decrease likely resides in the worst pathology observed in 3xTg-AD females in comparison to 3xTg-AD males. Indeed, 3xTg-AD females have repeatedly been reported to have, in particular, higher hAPP and Aβ levels than males60,62,63. Alternatively, a compensatory mechanism linked to the encoding of other NLGNs by sex chromosomes64,65, could also contribute to the sex-dependent decrease in NLGN1. Of interest is also that we found a genotype-independent decrease in NLGN1 level with age in male mice (also significant when females and males are pooled). This age-dependent decrease in hippocampal NLGN1 could definitely contribute to the main risk factor for neurodegeneration, namely age. More precisely, a progressive decrease in NLGN1 in the hippocampus may increase the susceptibility of this key brain region to synaptic and cell loss, such as under exposure to Aβo.

Our discovery that NLGN1 level in the hippocampus of MCI individuals and AD patients significantly correlates with soluble Aβ could suggest a specific contribution of the Aβ pathology in decreasing NLGN1 level. We indeed specifically found that exposure to Aβo reduces NLGN1 level in cultured hippocampal neurons, similar to a recent study66. From these data, we cannot exclude a direct effect of neuronal death on NLGN1 level because in vitro37,38. Such a direct interaction may contribute to an increased NLGN1 expression linked to epigenetic modifications such as what has been observed for Aβ fibrils36. An impact of Aβo on Nlgn1 gene expression is indeed supported by our findings in chronic hippocampal injections. Importantly, the different durations of Aβo treatment we have used allowed for the observation of a bi-phasic time course comprising an initial increase followed by a decrease. Moreover, this expression pattern was found only for specific Nlgn1 variants and not for other variants or other related genes (i.e, Nlgn2, Nrnxns). In fact, the initial increase was observed for Nlgn1 without insert in splice site A, and the following decrease for Nlgn1 without insert in sites A and B. These changes were substantial enough to be also captured by the common probe, but strongly suggest that the expression of Nlgn1 without insert is primarily affected by Aβo. In contrast with other isoforms, the isoform of NLGN1 not containing any insert is located equally at glutamatergic and

Figure 6. NLGN1 absence induces neuronal loss after Aβo exposure. (A) Representative IF images of NeuN staining (green) in the full hippocampus. The approximate location of the counting area is indicated by the yellow rectangle. Magnification 2.5X. (B) Representative IF images of NeuN staining (green) in the DG, where neuron counting was conducted. One image per group is showing approximately the same position within the DG. Magnification 40X. (C) Quantification of the area covered by the counting zone, which did not significantly differ between groups (two-way ANOVA Genotype main effect: F1,20 = 0.6, p = 0.4; Treatment main effect: F1,20 = 0.1 p = 0.8; Genotype-by-Treatment interaction: F1,20 = 0.2, p = 0.7). (D) Number of NeuN-marked cells counted in the DG target area showed a significant Genotype-by-Treatment interaction (two-way ANOVA F1,20 = 8.1, p = 0.01), with the KO Aβ group showing a significant difference in the number of immunoreactive cells in comparison to all other groups (star indicates planned comparisons). The number of mice is 6 per group.
gamma-aminobutyric acid (GABA) synapses\textsuperscript{57}. This could suggest that the negative impact on NLGN1 could play a role in GABAergic synapse dysfunctions observed in AD and animal models\textsuperscript{68,69}, as well as in glutamatergic synapse modifications\textsuperscript{4,12,21}. Besides, the initial increase in Nlgn1 expression after 2 days of A/\textsubscript{3}O exposure might belong to a neuroprotective pathway similar to other pathways driven by A/\textsubscript{3} in the hippocampus\textsuperscript{60}. NLGN1 was already shown to protect against oxidative stress in a non-mammalian model\textsuperscript{71} and to express neuroprotective functions in hippocampal neurons\textsuperscript{48,72}. Alternatively, lower Ngrl1 expression at 4 days of A/\textsubscript{3}O exposure may result from an increased expression with the vehicle injection, which could also be linked to a neuroprotective role of NLGN1 in response simply to intra-hippocampal injections. This effect would again be very specific to Ngrl1 lacking any insert and would be counteracted by A/\textsubscript{3}O exposure. The fact that a modulation by chronic A/\textsubscript{3}O hippocampal injections could not be detected at the protein level likely results from the absence of an isoform-specific antibody. Indeed, a change in NLGN1 isoform without insert could be masked by the absence of change in NLGN1 with insert B, which transcript is highly expressed in the hippocampus\textsuperscript{67}.

In the second part of our study, we provide data supporting a modulatory role of NLGN1 on spatial learning deficit and neuronal loss mediated by exposure of the hippocampus to A/\textsubscript{3}O\textsubscript{1-42}. Firstly, Ngrl1 KO mice injected with A/\textsubscript{3}O\textsubscript{1-42} were the only group showing memory impairment in SOR. A similar finding was made in the MWM training phase, during which Ngrl1 KO mice injected with A/\textsubscript{3}O\textsubscript{1-42} showed a longer overall latency to reach the platform. Deficits have been observed in KO mice with a lower exposure/dose than those generally inducing impairments in SOR and the MWM task in WT animals\textsuperscript{25,27,29}. Ngrl1 KO mice were previously shown to have only a very subtle deficit in the MWM and to have a preserved locomotion\textsuperscript{15}, which are in line with our observations of very few deficits in vehicle-injected KO mice. The fact that KO mice injected with A/\textsubscript{3}O\textsubscript{1-42} were impaired specifically in the MWM training phase, whereas Ngrl1 KO mice are not\textsuperscript{16}, also emphasizes a more specific implication of NLGN1 in modulating A/\textsubscript{3}O-induced deficits in learning or in memory acquisition. Of note is that this effect of NLGN1 seems restricted to spatial memory given that working memory involving a great extent the cerebral cortex\textsuperscript{75,76}. The manner by which NLGN1 modulates spatial learning deficits mediated by A/\textsubscript{3}O will need to be determined in future studies. Yet, the literature could point to mechanisms related to direct physical interactions between NLGN1 and A/\textsubscript{3}O\textsubscript{1-42} potentially sequestering toxic oligomers, or linked to NLGN1 cleavage that occurs in response to sustained synaptic activity\textsuperscript{77}.

Secondly, neuronal count in the DG was decreased only in Ngrl1 KO mice. The absence of NLGN1 thus seems to increase the neurotoxicity of A/\textsubscript{3}O by inducing neuronal loss following an intermediate exposure (i.e., 4 days) whereas neuronal loss is generally obtained from longer exposure (i.e., 6 days) or higher doses\textsuperscript{49,72,74}, similar to memory deficits. It should be noted, however, that the NeuN staining used here is not a direct indication of neuronal death, but that other accepted markers of neurodegeneration such as Caspase-3 and Fluoro-Jade B\textsuperscript{27} could not be used in the present study due to the sacrifice of animals being performed multiple days after exposure to allow for the evaluation of memory. Nevertheless, our finding supporting that NLGN1 can oppose A/\textsubscript{3}O-driven neurotoxicity in the DG is in line with observations that a soluble fragment of NLGN1 diminishes the negative impact of A/\textsubscript{3}O on excitatory synaptic transmission in hippocampal slices\textsuperscript{48} and that NLGN1 is part of a pathway counteracting A/\textsubscript{3}O-induced synaptotoxicity in cultured hippocampal neurons\textsuperscript{88}.

Conclusions

We here reveal that NLGN1 is decreased in the hippocampus of patients with prodromal signs of and established neurodegeneration in a symptomatology-dependent manner and, using \textit{in vitro} and \textit{in vivo} models, that this change is likely driven, at least in part, by A/\textsubscript{3}O and contributing to cognitive decline. In parallel, our data expose a bi-directional relationship between NLGN1 and A/\textsubscript{3}O, in which the accumulation of A/\textsubscript{3}O\textsubscript{1-42} negatively impacts NLGN1, and decreased NLGN1 renders neurons/synapses more vulnerable to A/\textsubscript{3}O\textsubscript{1-42} translating in memory deficits and neuronal loss. Our findings support a potential for strategies enhancing NLGN1 to alleviate symptoms of AD, which reconciles with previous research\textsuperscript{48,50,58}, including with that reporting NRXN-NLGN mutations in AD patients\textsuperscript{44,35}. On the contrary, our study does not support approaches opposing NLGN1 as a therapeutic strategy in AD such as the use of anti-NLGN1 antibody\textsuperscript{47}. The current research provides additional insight in the development of early diagnostic tools and treatments of aMCI and AD, which is of crucial importance to benefit the quality of life of millions of AD patients worldwide.

Received: 10 December 2019; Accepted: 27 March 2020; Published online: 24 April 2020

References

1. Pozueta, J., Lefort, R. & Shelandi, M. L. Synaptic changes in Alzheimer's disease and its models. Neuroscience. 251, 51–65 (2013).
2. Terry, R. D. \textit{et al.} Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Am. Neurol. 30, 572–580 (1991).
3. Sindl, I. A., Tannenberg, R. K. & Dodd, P. R. Role for the neurexin-neuroligin complex in Alzheimer's disease. Neurobiol. Aging. 35, 746–756, https://doi.org/10.1016/j.neurobiolaging.2013.09.032 (2014).
4. Pini, L. \textit{et al.} Brain atrophy in Alzheimer's Disease and aging. Ageing Res. Rev. 30, 25–48 (2016).
5. Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M. & Waldhorn, K. B. Alzheimer's Disease Neuroimaging Initiative. What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog. Neurobiol. 117, 20–40 (2014).
6. Scheff, S. W. & Price, D. A. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J. Alzheimers Dis. 9, 101–115 (2006).
7. Gómez-Isla, T. \textit{et al.} Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491–4500 (1996).
21. Shankar, G. M. & Lacor, P. N. Neurexin-neuroligin signaling in synapse development. J. Neurosci. 30, 2442–2453 (2010).
26. Südhof, T. C. Neuroligins and neurexins link synaptic function to cognitive disease. Neuron. 35, 352–358 (2000).
27. Craig, A. M. & Kang, Y. Neurexin-neuroligin signaling in synapse development. J. Neurosci. 30, 2442–2453 (2010).
31. Shen, H. F. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Ann. Neurol. 46, 860–866 (1999).
32. Wu, X. & Brouillette, J. The effects of soluble Aβ oligomers on synapse development in Alzheimer's disease. Curr. Pharm. Des. 20, 2506–2519 (2014).
33. Blundell, J. A. et al. Functional significance of rare neuroligin 1 variants found in autism. PLoS Genet. 13, e1006940, https://doi.org/10.1371/journal.pgen.1006940 (2017).
34. Ocwarczak, S., Bang, M. L. & Berezin, V. Neurexin-Neuroligin synaptic complex regulates schizophrenia-related DSC1/Kal-7/Rac1 "signalosome". Neurol. 157, 2578–2587 (2014).
35. Mclean, C. A. et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860–866 (1999).
36. Nakanishi, M. et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866–2875 (2007).
37. JAMA. The genome-wide landscape of DNA methylation and hydroxymethylation in response to sleep deprivation. Proc. Natl. Acad. Sci. USA 112, 166–178 (2015).
38. Dinamarca, M. C., Di Luca, M., Godoy, J. A. & Inestrosa, N. C. The soluble extracellular fragment of neuroligin-1 targets Aβ oligomers to the postsynaptic region of excitatory synapses. Biochem. Biophys. Res. Commun. 297, 66–71 (2009).
39. Hepler, R. W. & McCormick, C. R. Abeta oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J. Neurosci. 30, 2442–2453 (2010).
40. Tomic, J. et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27, 224–233 (2008).
41. Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D. & Schwartz, J. B. Declining levels of functionally specialized synaptic proteins correlate with cognitive dysfunction. MBio. 27, 796–807 (2007).
42. Lacor, P. N. et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27, 796–807 (2007).
77. Gutiérrez, I. L.
76. Yang, S. T., Shi, Y., Wang, Q., Peng, J. Y. & Li, B. M. Neuronal representation of working memory in the medial prefrontal cortex of
73. Zamani, E., Parviz, M., Roghani, M. & Mohseni-Moghaddam, P. Key mechanisms underlying netrin-1 prevention of impaired
70. Tao, C. C., Hsu, W. L., Ma, Y. L., Cheng, S. J. & Lee, E. H. Epigenetic regulation of HDAC1 SUMOylation as an endogenous
62. Hirata-Fukae, C.
61. Muñoz-Cabrera, J. M.
67. Chih, B., Gollan, L. & Scheiffele, P. Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin
66. Kim, D. H.
65. Jamain, S.
64. Dang, R.
63. Vandal, M.
60. Virgili, J., et al. Characterization of a 3xTg-AD mouse model of Alzheimer’s disease with the senescence accelerated mouse prone 8
58. Karlsson, M. P. & Frank, L. M. Network dynamics underlying the formation of sparse, informative representations in the
57. Billings, L. L., Oddo, S., Green, K. N., McGaugh, J. L. & LaFerla, F. M. Intraneuronal Abeta causes the onset of early Alzheimer’s
disease-related cognitive deficits in transgenic mice. Neuron. 45, 675–688 (2005).
56. Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183–194 (2004).
55. Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National
Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 270–279 (2011).
53. Castonguay, D. et al. The tyrosine phosphatase STEP is involved in age-related memory decline. Curr. Biol. 28, 1079–1089.e4 (2018).
54. Gusel’nikova, V. V. & Korzhhevskyi, D. E. NeuN as a neuronal nuclear antigen and neuron differentiation marker. Acta Naturae. 7, 42–47 (2015).
52. Best, P. L. White, A. M. & Minai, A. Spatial processing in the brain: the activity of hippocampal place cells. Annu. Rev. Neurosci. 24, 459–486 (2001).
51. Virgili, J. et al. Characterization of a 3xTg-AD mouse model of Alzheimer’s disease with the senescence accelerated mouse prone 8 (SAMP8) background. Synapse. 72(4), https://doi.org/10.1002/syn.22025 (2018).
50. Muñoz-Cabrera, J. M. et al. Bezafibrate therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer’s disease. PLoS One. 14(10), e0223578, https://doi.org/10.1371/journal. pone.0223578 (2019).
49. Hirata-Fukae, C. et al. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 1216, 92–103, https://doi.org/10.1016/j.brainres.2008.03.079 (2008).
48. Vandal, M. et al. Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer’s disease. FASEB J, 29, 4273–4284, https://doi.org/10.1096/fj.14-268482 (2015).
47. Dan, R. et al. Regulation of hippocampal long term depression by Neuroginin 1. Neuropharmacology. 143, 205–216 (2018).
46. Jamain, S. et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 34, 27–29 (2003).
45. Kim, D. H. et al. Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimer’s disease model. Sci. Rep. 8, 354, https://doi.org/10.1038/s41598-017-18542-0 (2018).
44. Chih, B., Gollan, L. & Scheiffele, P. Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin complex. Neuron. 51, 171–178 (2006).
43. Ambrad Giovannetti, E. & Fuhrmann, M. Unsupervised excitation: GABAergic dysfunctions in Alzheimer’s disease. Brain Res. 1707, 216–226 (2019).
42. Li, Y. et al. Synaptic adhesion molecule Pedh~to~CS mediates synaptic dysfunction in Alzheimer’s disease. J. Neurosci. 37, 9259–9268 (2017).
41. Tao, C. C., Hsu, W. L., Ma, Y. L., Cheng, S. J. & Lee, E. H. Epigenetic regulation of HDAC1 SUMOylation as an endogenous
neuroprotection against Aβ toxicity in a mouse model of Alzheimer’s disease. Cell Death Differ. 24, 597–614 (2017).
40. Staab, T. A., Evgrafov, O., Knowles, J. A. & Sieburch, D. Regulation of synaptic nlg1-neuroligin abundance by the skn-1/Nrf stress
response pathway protects against oxidative stress. PLoS Genet. 10, e1004100, https://doi.org/10.1371/journal.pgen.1004100 (2014).
39. Peixoto, R. T. et al. Transsynaptic signaling by activity-dependent cleavage of neuroligin-1. Neuro. 76, 396–409 (2012).
38. Zamani, E., Parviz, M., Roghani, M. & Mohseni-Moghaddam, P. Key mechanisms underlying netrin-1 prevention of impaired
spatial and object memory in A31-42 CA1-injected rats. Clin. Exp. Pharmacol. Physiol. 46, 86–93 (2019).
37. Wang, M., Li, Y., Ni, C. & Song, G. Honokiol attenuates oligomeric amyloid β-41-42-induced Alzheimer’s disease in mice through
attenuating mitochondrial apoptosis and inhibiting the nuclear factor kappa-B signaling pathway. Cell Physiol. Biochem. 43, 69–81 (2017).
36. Xie, J., Bai, W., Liu, T. & Tian, X. Functional connectivity among spike trains in neural assemblies during rat working memory task.
Behav. Brain Res. 274, 248–257 (2014).
35. Yang, S. T., Shi, Y., Wang, Q., Peng, J. Y. & Li, B. M. Neuronal representation of working memory in the medial prefrontal cortex of
rats. Mol. Brain. 7, 61, https://doi.org/10.1186/s13041-014-0061-2 (2014).
34. Gutiérrez, I. L. et al. Alternative method to detect neuronal degeneration and amyloid ß accumulation in free-floating brain sections
with Fluoro-Jade. ASN Neuro. 10, 1759091418784357, https://doi.org/10.1177/1759091418784357 (2018).
33. Lu, X. et al. Epigenetic mechanisms underlying the effects of triptolid and triphloridin on the expression of neuroligin-1 in the
hippocampus of APP/PS1 transgenic mice. Pharm. Biol. 57, 453–459 (2019).

Acknowledgements
Authors are thankful to Erika Belanger-Nelson and Caroline Bouchard for technical help. This work was supported by grants from the Fonds de recherche du Que¨bec - Santé (FRQS), the Natural Sciences and Engineering Research Council of Canada (RGPIN-2016-05504) and the Hôpital du Sacré-Coeur de Montréal (Recherche CIUSSS-NIM) to J.B.; by a grant from the Canadian Institutes of Health Research (231095-111021) and the Canada Research Chair in Sleep Molecular Physiology held by V.M.; by a grant from the National Institutes of Health (P30AG028383) to the Alzheimer’s Disease Center of the University of Kentucky; by a FRQS Junior 1 Research Scholar (33204) to J.B.; by a FRQS Senior Research Scholar (253895) to F.C.; by fellowships from the Hôpital du Sacré-Coeur de Montréal and the Department of Pharmacology of the Université de Montréal awarded to J.D.G.; and by a fellowship of the Faculty of Medicine of the Université de Montréal to L.C..

Author contributions
J.D.G. performed experiments related to injection of Aβo, analyzed the data, produced all figures, and wrote the
manuscript. C.P. provided help with animal handling and care in the context of experiments related to injection of
amyloid-beta oligomers. L.C. performed immunohistochemistry of brain injected with Aβo and analyzed images
of staining. C.M.N. provided human samples. E.C. provided 3xTg-AD mouse brain tissues. V.M. and J.B. designed
experiments related to injection of Aβo, supervised all analyses, and wrote the manuscript. All authors read and
approved the final manuscript.

Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-63255-6.

Correspondence and requests for materials should be addressed to V.M. or J.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020